Sign inJoin waitlistJoin the waitlist

Steven Yukl

Professor in Residence · University of California (San Francisco) School of Medicine

Credentials: · ·

History

University of California (San Francisco) School of Medicine
Present

Infectious Disease
University of California-San Francisco
2002–2004
Internal Medicine-Pediatrics
Duke University Hospital
2000–2004
06/2000 - Medicine, University of Michigan at Ann Arbor
1996–2000

Research

Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies
PLoS Pathogens · 2013 · 500 citations
HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing
Science Translational Medicine · 2018 · First of 8 authors · Corresponding · 294 citations
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
The Journal of Infectious Diseases · 2010 · First of 21 authors · Corresponding · 259 citations

Joseph Wong
42 papers
Steven Deeks
35 papers
Peter Hunt
15 papers
Ma Somsouk
13 papers
Sulggi Lee
12 papers
Diane Havlir
9 papers
HH
Hiroyu Hatano
9 papers
SP
Satish Pillai
8 papers
DR
Douglas Richman
7 papers
Timothy Henrich
6 papers
Warner Greene
6 papers
Chuanyi Lu
5 papers

Grants

Understanding and Targeting the HIV-Expressing Reservoir to Reduce Immune Activation
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $2.4M · Northern California Institute/Res/Edu
2024–2029
The Heterogeneous HIV Expressing Reservoir: Dynamics, Persistence Mechanisms, Tissue Distribution, and Contribution to Rebound
National Institute of Allergy and Infectious Diseases · P01
Contact PI · $7.8M · University of California, San Francisco
2022–2027
Novel Single Genome Approaches to Determine the Mechanisms of HIV Latent Infection in Blood, Gut, and Lymph Nodes
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $4.1M · Northern California Institute/Res/Edu
2019–2026
Understanding HIV Latency Reversal and Clearance of Infected Cells in vivo
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $1.9M · Northern California Institute/Res/Edu
2017–2024

Clinical trials

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
Principal investigator · Completed
University of California, San Francisco
2008–2010